Tau Isoform-Specific Antibodies for Tauopathy Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches lack specificity and effectiveness in targeting tau protein isoforms, particularly 4 R and 3 R tau, which are implicated in tauopathies such as progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia, necessitating the development of antibodies that can selectively bind these isoforms for accurate detection and treatment.
Innovation Solution
Development of antibodies and antigen-binding fragments that specifically bind 4 R or 3 R tau protein isoforms by targeting unique epitopes, including regions encoded by exon 10 for 4 R tau and the junction between exons 9 and 11 for 3 R tau, with high affinity and specificity, allowing for detection and potential therapeutic intervention in tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic and therapeutic approaches are used, then general tau protein detection is achieved, but specificity for particular tau isoforms (4 R and 3 R) is insufficient
Solution Approach 1:
The patent segments the tau protein detection by developing antibodies that specifically target distinct epitopes unique to 4 R tau (exon 10 encoded region) and 3 R tau (exon 9-11 junction region). This segmentation allows differential detection of isoforms that were previously indistinguishable by current approaches
Solution Approach 2:
The invention applies local quality by designing antibodies with specific binding characteristics for particular regions: one antibody targets the exon 10 encoded region (unique to 4 R tau) while another targets the exon 9-11 junction region (unique to 3 R tau). Each antibody has optimized local binding properties for its specific epitope, enabling isoform-specific detection
2Measurement precision
If antibodies targeting unique epitopes are developed, then specificity for 4 R or 3 R tau isoforms is improved, but complexity of antibody development and characterization increases
Solution Approach 1:
The patent extracts the essential distinguishing feature between 4 R and 3 R tau isoforms by focusing on specific epitope regions: the exon 10 encoded region for 4 R tau and the exon 9-11 junction region for 3 R tau. By extracting and targeting these specific regions, the complexity of developing isoform-specific antibodies is reduced to focusing on key discriminative epitopes rather than the entire protein structure
3Reliability
If high affinity binding to unique epitopes is achieved, then therapeutic effectiveness in shifting tau isoform balance is improved, but difficulty in detecting and measuring binding specificity increases
Solution Approach 1:
The patent uses peptide intermediaries corresponding to the unique epitope regions (exon 10 encoded peptide for 4 R tau, exon 9-11 junction peptide for 3 R tau) as mediators to facilitate measurement of antibody binding specificity. These peptide intermediaries serve as standardized probes that enable quantitative assessment of binding affinity and specificity without requiring complex whole-protein assays
Data Source
AI summary
The present invention provides an antibody or antigen-binding fragment thereof that: (a) specifically binds 4R tau protein isoforms in a physiological sample; or (b) specifically binds 3R tau protein isoforms in a physiological sample. The present invention further provides nucleic acids and vectors encoding such an antibody or antigen-binding fragment, as well as host cells comprising such nucleic acids and vectors. The antibodies and fragments may be used in treating and diagnosing tauopathies.